X

Trump Administration Passed on Chance to Secure More of Pfizer Vaccine

The pharmaceutical company offered the government a chance to lock in additional supplies before its vaccine was proved effective in clinical trials.

WASHINGTON — Before Pfizer’s coronavirus vaccine was proved highly successful in clinical trials last month, the company offered the Trump administration the chance to lock in supplies beyond the 100 million doses the pharmaceutical maker agreed to sell the government as part of a $1.95 billion deal over the summer.

But the administration, according to people familiar with the talks, never made the deal, a choice that now raises questions about whether the United States allowed other countries to take its place in line.

While two vaccines, including Pfizer’s, have proved to be highly effective against Covid-19, and a third also appears at least moderately effective, supplies are shaping up to be scarce in the coming months as infections, hospitalizations and deaths surge to new highs. And while Pfizer is now negotiating with the administration to provide more of its vaccine, people familiar with the talks say the company cannot guarantee that it will be able to deliver more than the initial 100 million doses — enough to inoculate 50 million people since its vaccine requires two shots — before perhaps next June. Continue reading.

Data and Research Manager: